KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that in association with Immunitor Inc, the Company will seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority. Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is p
December 1, 2020
· 5 min read